A Novel Approach to Extensive Clarithromycin-Resistant Mycobacterium avium Complex Pulmonary Disease

Ann Thorac Cardiovasc Surg. 2022 Dec 20;28(6):444-447. doi: 10.5761/atcs.cr.21-00010. Epub 2021 May 8.

Abstract

A 48-year-old woman with extensive clarithromycin-resistant Mycobacterium avium complex pulmonary disease (MAC-PD) was successfully treated by left lower lobectomy and lingulectomy following combination treatment of intravenous/inhaled amikacin plus bronchial occlusion by Endobronchial Watanabe Spigots (EWSs). A left pneumonectomy was initially indicated for removing all the lesions, but the procedure would have been barely tolerated by the patient. However, her preoperative combination treatment sufficiently reduced the lesions requiring resection to allow surgical preservation of the left upper division. This novel approach might be promising for patients with Mycobacterium avium complex lung disease whose pulmonary reserve will not allow an extensive parenchymal resection.

Keywords: Endobronchial Watanabe Spigot; Mycobacterium avium complex; amikacin; bronchial occlusion; clarithromycin-resistant.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Clarithromycin / therapeutic use
  • Female
  • Humans
  • Lung Diseases* / diagnostic imaging
  • Lung Diseases* / drug therapy
  • Middle Aged
  • Mycobacterium avium Complex
  • Mycobacterium avium-intracellulare Infection* / diagnosis
  • Mycobacterium avium-intracellulare Infection* / drug therapy
  • Mycobacterium avium-intracellulare Infection* / microbiology
  • Treatment Outcome

Substances

  • Clarithromycin
  • Anti-Bacterial Agents